A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis by Yong Huang et al.
RESEARCH ARTICLE Open Access
A functional genomic model for predicting
prognosis in idiopathic pulmonary fibrosis
Yong Huang1†, Shwu-Fan Ma1†, Rekha Vij1†, Justin M. Oldham1, Jose Herazo-Maya2, Steven M. Broderick1,
Mary E. Strek1, Steven R. White1, D. Kyle Hogarth1, Nathan K. Sandbo1, Yves A. Lussier3,4, Kevin F. Gibson5,
Naftali Kaminski2, Joe G. N. Garcia6 and Imre Noth1*
Abstract
Background: The course of disease for patients with idiopathic pulmonary fibrosis (IPF) is highly heterogeneous.
Prognostic models rely on demographic and clinical characteristics and are not reproducible. Integrating data from
genomic analyses may identify novel prognostic models and provide mechanistic insights into IPF.
Methods: Total RNA of peripheral blood mononuclear cells was subjected to microarray profiling in a training
(45 IPF individuals) and two independent validation cohorts (21 IPF/10 controls, and 75 IPF individuals, respectively).
To identify a gene set predictive of IPF prognosis, we incorporated genomic, clinical, and outcome data from
the training cohort. Predictor genes were selected if all the following criteria were met: 1) Present in a gene
co-expression module from Weighted Gene Co-expression Network Analysis (WGCNA) that correlated with
pulmonary function (p < 0.05); 2) Differentially expressed between observed “good” vs. “poor” prognosis with fold
change (FC) >1.5 and false discovery rate (FDR) < 2 %; and 3) Predictive of mortality (p < 0.05) in univariate Cox
regression analysis. “Survival risk group prediction” was adopted to construct a functional genomic model that used
the IPF prognostic predictor gene set to derive a prognostic index (PI) for each patient into either high or low risk
for survival outcomes. Prediction accuracy was assessed with a repeated 10-fold cross-validation algorithm and
independently assessed in two validation cohorts through multivariate Cox regression survival analysis.
Results: A set of 118 IPF prognostic predictor genes was used to derive the functional genomic model and PI. In
the training cohort, high-risk IPF patients predicted by PI had significantly shorter survival compared to those
labeled as low-risk patients (log rank p < 0.001). The prediction accuracy was further validated in two independent
cohorts (log rank p < 0.001 and 0.002). Functional pathway analysis revealed that the canonical pathways enriched
with the IPF prognostic predictor gene set were involved in T-cell biology, including iCOS, T-cell receptor, and
CD28 signaling.
Conclusions: Using supervised and unsupervised analyses, we identified a set of IPF prognostic predictor genes
and derived a functional genomic model that predicted high and low-risk IPF patients with high accuracy. This
genomic model may complement current prognostic tools to deliver more personalized care for IPF patients.
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Background
Idiopathic pulmonary fibrosis (IPF) is a fibrotic interstitial
lung disease characterized by irreversible scarring of the
lung parenchyma that predominantly affects older adults.
While older retrospective studies suggested median sur-
vival was 2–3 years [1–3], IPF has a highly heterogeneous
disease course, making prognostication difficult [4, 5].
While lung transplantation remains the sole intervention
to prolong survival in patients with IPF [6], organ scarcity,
and ineligibility secondary to comorbid health conditions,
make this available to only a few. Pirfenidone [7] and nin-
tedanib [8] have emerged as promising therapies that slow
disease progression. Several other medications are cur-
rently under investigation. Without the ability to predict
disease course, it is difficult to identify which IPF patients
are most likely to benefit from these new therapies or
from lung transplantation.
Many clinical parameters, including race, gender, age,
radiographic and/or histopathologic patterns, and pul-
monary function tests have been linked to prognosis in
patients with IPF [9, 10]. Lung tissue-based molecular
genomic signatures [11, 12] have also been used to predict
IPF progression; however, given the resources needed to
perform lung biopsy and risk associated with the proced-
ure, the applicability of such genomic signatures is limited.
Peripheral blood mononuclear cells (PBMC), comprised
of circulating monocytes, T-cells, B-cells, and natural killer
cells, have been successfully used as an alternative for ex-
ploratory transcriptional profiling studies [13–15]. Advan-
tages of using PBMC over lung biopsy specimens to
delineate molecular mechanisms of IPF include easier ac-
cess, larger quantities, and the ability to dynamically assess
disease status through longitudinal sample collection.
Using PBMC gene expression profiling, our group previ-
ously identified a genomic signature consisting of 52 genes
that predicted survival in patients with IPF [16]. While this
investigation drew attention to the potential role of T cell
signaling in IPF progression, the contribution of other
genes identified in the study were not addressed. Further-
more, the gene set identified from our previous study did
not provide a weighted score for the gene expression pat-
tern, which has the potential to be useful in practical appli-
cation. We therefore aim to construct a functional genomic
model to better predict prognosis of IPF patients. To do so,
we compiled a set of IPF prognostic predictor genes from
previously reported microarray data in the training cohort
(accession number GSE28221) [17, 18]. First, we coupled
PBMC gene expression profiling to IPF clinical traits using
an unbiased “Weighted Gene Co-expression Network
Analysis (WGCNA)” approach which is useful for describ-
ing the pairwise correlated expression among gene tran-
scripts with co-regulation implications [19–21] and to
restrict the search space of genes to those genes in modules
associated with pulmonary function. Second, we performed
a supervised “Significance Analysis of Microarray (SAM)”
approach to identify differentially expressed genes between
observed “good” vs. “poor” prognosis IPF patients. Third,
we identified genes based on their association with sur-
vivorship. The IPF prognostic predictor gene set satisfying
all aforementioned three functional genomic criteria was
used to construct a genomic prediction model and derived
a prognostic index (PI) score for each patient in the training
cohort. We then assessed the prognostic prediction specifi-
city in the training cohort and further validated it in two
independent cohorts. This work produced a functional gen-
omic model with a mechanism-anchored IPF prognostica-
tion score for each patient, which may better identify those
most likely to benefit from IPF-specific therapy and provide
a tool for personalized IPF management.
Methods
Study populations
Study populations were collected, as previously described,
from the University of Chicago Medical Center (UCMC )
and University of Pittsburg Medical Center (UPMC) [16].
The training cohort consisted of 45 individuals with IPF
collected from November 2007 to July 2009 at UCMC.
The University of Chicago validation cohort (UCV) con-
sisted of 21 individuals with IPF along with 10 healthy con-
trol subjects without lung disease collected from February
2007 to October 2007. The University of Pittsburg valid-
ation cohort (UPV) consisted of 75 individuals with IPF
collected from March 2001 to September 2010. While the
site source of the samples overlapped between cohorts, all
samples were independent of each other. All patients with
IPF met American Thoracic Society/European Respiratory
Society (ATS/ERS) diagnosis criteria [2]. The local Institu-
tional Review Boards at the University of Chicago and
University of Pittsburg Medical Center approved the study
and informed consent was provided by all study subjects.
Demographic information, clinical characteristics, and
pulmonary function tests were collected from all pa-
tients with IPF. Spirometry testing, including forced vital
capacity percent predicted (FVC% predicted), diffusion
capacity for carbon monoxide percent predicted (DLCO %
predicted) as well as lung volumes by plethysmography
were obtained per ATS guidelines [19–21]. The composite
physiologic index (CPI) was calculated as described by
Wells et al. [22]. Survivorship was obtained from medical
records, telephone interviews, and the social security
death index database. The prognosis of IPF subjects was
dichotomously categorized as good or poor based on ob-
served survival over 3 years of follow-up.
PBMC sample collection, RNA isolation, microarray
hybridization, and data processing
See details in Additional file 1. Microarray experiments
were compliant with MIAME (Minimum Information
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About a Microarray Experiment) guidelines. The complete
data sets are available in the Gene Expression Omnibus
database (http://www.ncbi.nlm.nih.gov/geo/) under acces-
sion number GSE28221.
Identification of gene co-expression modules correlated
with clinical traits in training cohort
Normalized microarray data were filtered to remove re-
dundant genes and genes with minimum variation (i.e.
coefficient of variation <0.3 across all samples). Genes
that passed filtering criteria were clustered into gene
modules, based on their co-expression pattern, using an
unsupervised “Weighted gene co-expression network
analysis (WGCNA)” package in R 2.13 [23]. Principal
Component Analysis (PCA) was used to calculate an
eigengene for each gene module. Pearson’s correlation was
used to determine the significance of correlation (p < 0.05)
between the eigengenes of individual gene modules with
each clinical parameter including race, sex, age, FVC %
predicted, DLCO % predicted, and CPI.
Identification of differentially expressed genes in the
training cohort
Significant Analysis of Microarray (SAM) software [24]
was used to identify differentially expressed genes be-
tween observed good vs. poor IPF prognosis using cri-
teria of fold change (FC) >1.5 and false discovery rate
(FDR) < 2 %.
Survival analysis
Survival analysis was performed using unadjusted log rank
testing along with univariate and/or multivariate Cox re-
gression analysis. After checking to ensure that the pro-
portional hazard assumption was met with each Cox
model, subdistributional mortality hazards were deter-
mined for covariates by treating lung transplantation as a
competing event, as previously described by Fine and Gray
[25]. Survival time was defined as time from blood draw
to death, transplant, loss-to-follow-up or study conclusion.
Patients who were lost to follow-up were censored at that
time in survival modeling. Survival between groups was
plotted using the Kaplan-Meier estimator.
Compilation of the IPF prognostic predictor gene set
from the training cohort for a genomic model
construction
To construct a functional genomic model predictive of
IPF prognosis, genomic, clinical, and outcome data from
the training cohort were analyzed to identify a set of
genes with individual prognostic significance. Genes
were selected for the “IPF prognostic predictor gene set”
if they met all of the following criteria: 1) genes in spe-
cific gene co-expression modules that correlated with
pulmonary function (p < 0.05) in WGCNA, 2) genes
differentially expressed (FC > 1.5 and FDR < 2 %) be-
tween observed good vs. poor prognosis by SAM, and 3)
genes predictive of mortality (p < 0.05) in univariate Cox
regression analysis.
Development and validation of the functional genomic
model to predict prognosis
The set of IPF prognostic predictor genes identified was
used to construct a genomic model using “Survival risk
group prediction” implemented in BRB-ArrayTools 4.2
[26] to predict prognosis in IPF patients. The output of
the genomic model is a patient-specific “prognostic index
(PI)” score. PI of each patient in training cohort was
derived from formula, ∑Wi * Xi + 13.5, where Wi and
Xi represent the weight (computed by supervised
PCA) and log-intensity of the i-th gene in the gene
set. To assign a patient to either a high- or low-risk
group, each patient’s PI was compared to a predetermined
classification threshold. For this study, the threshold was
set at the upper tertile in the training cohort according to
clinical observation [3]. A “10-fold Cross-Validation (CV)”
algorithm was used to assess the classification specificity.
Briefly, 10 % of patients were randomly omitted leaving the
remaining 90 % of patients to construct the genomic model
and derive a PI for each of the omitted samples. The PI of
omitted individuals was then ranked relative to the PI of
patients included in the CV model. Finally, we determined
the predicted risk category based on the percentile ranking,
the number of risk groups specified (i.e. n = 2 in current
study), and the empirical risk percentile setting (i.e. low/
high risk = 66.7/33.3). Misclassification rate was determined
by the discrepancy between the predicted low or high-risk
category with the observed good or poor prognosis accord-
ing to follow-up. Receiver-Operating-Characteristic (ROC)
analysis with area under curve (AUC) calculation was per-
formed to assess how well the PI distinguished IPF patients
with low vs. high-risk prognosis. To perform an independ-
ent validation of the predictor, we applied the PI weights
computed from the training set of 45 IPF samples to the
calculation of the PI on the UCV and UPV cohorts. Details
can be found in Additional file 1.
Functional pathways enrichment analysis
Significant biological processes in Gene Ontology associ-
ated with the set of IPF prognostic predictor genes were
identified using R package “GOSim” [27] with the criterion
of q-value (Benjamini-Yekutieli adjusted p-value) <0.01.
Significant canonical pathways or gene interaction net-
works were analyzed using Ingenuity Pathway Analysis
(IPA) software (Ingenuity Systems, Redwood City, CA) with
the criterion of the right-tailed (referring to the overrepre-
sented pathway) Fisher’s exact test q-value (Benjamini-
Hochberg adjusted p-value) <0.05.
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IPF diagnosis prediction using prognosis index derived
from the functional genomic model
Using the generated PI, ROC analysis with AUC calcula-
tion was performed in UCV cohort to assess how well
the PI distinguishes IPF patients from healthy controls.
The true positive rate (sensitivity) is plotted in function
of the false positive rate (1-specificity) for different cut-
off points. Each point on the ROC curve represents a
sensitivity/false alarm pair corresponding to a particular
decision threshold.
Statistical analysis
Continuous variables are reported as a mean (± standard
deviation) and compared using a one-way analysis of
variance. Categorical variables are reported as counts
and percentages and compared using a chi-square or
Fischer’s exact test, as appropriate. Pearson’s correlation
was used to evaluate the correlation of prognostic index
(PI) derived from genomic model with clinical parame-
ters. ROC analysis with AUC calculation was performed
using R package “caTools”. Other than when indicated
above, statistical analysis was conducted using STATA
12 (StataCorp. 2011. College Station, TX).
Results
Demographic and clinical characteristics of patients with
IPF
Demographic and clinical characteristics for each IPF co-
hort are shown in Table 1. Significant differences between
the training, UCV and UPV cohorts were observed with re-
spect to male gender (90 % vs. 71.4 % vs. 69.3 %, respect-
ively; p = 0.05), white race (82.2 % vs. 81.8 % vs. 97.3 %,
respectively; p = 0.004), follow-up months (18.8 vs. 43.8 vs.
23.5 months, respectively; p < 0.001), months to death
(12.7 vs. 26.8 vs. 14.2, respectively; p = 0.02) and lung trans-
plantation (2.2 % vs. 9.5 % vs. 20 %, respectively; p = 0.009).
No differences between cohorts were observed with
respect to age, FVC % predicted, DLCO % predicted
or CPI.
Identification of gene co-expression modules correlated
with clinical traits in training cohort
“WGCNA” package in R was utilized to cluster 2718
genes that passed the filtering criteria into eight gene
co-expression modules denoted by different colors
(Fig. 1). Optimization of the power for adjacency transi-
tion and the parameters for gene clustering dendrogram
are depicted in Additional file 2: Figure S1A and S1B, re-
spectively. The eigengene values of individual modules
were then computed by PCA and correlated with clinical
traits to envision the association between co-expressed
gene pattern features with clinical features [23]. The sig-
nificance of correlation with clinical traits was deter-
mined by Pearson’s correlation assay with p <0.05. As
shown in Fig. 1, three gene modules demonstrated sig-
nificant correlation (red box) or anti-correlation (green
box) with clinical traits: turquoise module with male
gender (p = 0.009), FVC % predicted (p = 0.0002), DLCO %
predicted (p = 0.005), and CPI (p = 0.002); red module
with FVC % predicted (p = 0.03); black module with
FVC % predicted (p = 0.002) and CPI (p = 0.03). Of note
that 1199, 157, and 131 genes consist of 55 % (1487/2718)
of total genes were clustered into turquoise, read, and
black modules, respectively (Fig. 1).
Compilation of the set of IPF prognostic predictor genes
In an effort to reduce the number of genes in turquoise,
red, and black modules associated with pulmonary func-
tion to a clinically applicable number and to incorporate
predictive prognostic feature to co-expressed gene pat-
tern feature, we applied two additional distinct ap-
proaches to the analytic pipeline (Fig. 2a). Using SAM,
we identified 155 that were differentially expressed (DE)
genes between IPF patients with good and poor prognosis.
Using univariate Cox regression analysis, we identified 836
genes which were significantly correlated with survival
(p < 0.05) (Fig. 2b). Notably, 147 of the 155 DE genes were
overlapped with the 1487 genes combined from the tur-
quoise, black, and red gene modules. This integrative func-
tional genomic approach yielded a set of 118 prognostic
Table 1 Demographic and Clinical Characterizations among Study Cohorts
Characteristic Training cohort (n = 45) UCV cohort (n = 21) UPV cohort (n = 75) p-value
Age, mean (±SD) 67.1 (8.2) 68.9 (8.2) 68.5 (7.8) 0.48
Male gender, n (%) 40 (90) 15 (71.4) 52 (69.3) 0.05
White race, n (%) 37 (82.2) 18 (81.8) 73 (97.3) 0.004
Follow-up months, mean (±SD) 18.8 (11.9) 43.8 (29.4) 23.5 (12.7) <0.001
Months to death, mean (±SD) 12.7 (10.9) 26.8 (20.1) 14.2 (10.6) 0.02
FVC % predicted, mean (±SD) 60.6 (14.3) 64.7 (12.7) 65.4 (16.7) 0.25
DLCO % predicted, mean (±SD) 43.4 (17.7) 43.2 (15.6) 48.9 (18.6) 0.19
CPI, mean (±SD) 55.6 (13) 54.7 (10.7) 50.7 (13.7) 0.11
Lung transplantation, n (%) 1 (2.2) 2 (9.5) 15 (20) 0.009
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predictor genes (Fig. 2b). A list of 118 prognostic predictor
genes attributed to turquoise (n = 110), red (n= 5), and
black (n = 3) modules was shown in Table 2.
Pathway and network characterization of the IPF
prognostic predictor genes
To assess the pathways and networks of the 118 IPF prog-
nostic predictor genes involved, we carried out a functional
enrichment analysis using Ingenuity pathway analysis (IPA)
and gene network analysis software. Surprisingly, all signifi-
cant canonical pathways with -log(q-value) > 1.3 were in-
volved in T-cell biology (Fig. 2c). Several genes were
involved in multiple T-cell signaling pathways, including
CD28 receptor (CD28), inducible T-cell co-stimulator
(ICOS), lymphocyte-specific protein tyrosine kinase (LCK),
interleukin 7 receptor (IL7R), and major histocompatibility
complex, class II, DQ alpha 1 (HLA-DQA1) (Additional
file 1: Table S1). Of note that these pathways comprised
genes mostly if not all in the turquoise module which
represent >93 % of genes in the IPF prognostic predictor
gene set.
Ingenuity network modeling based on “Ingenuity
Knowledge” database prioritized five significant gene
networks with score ≥ 32. Seventy-eight of the 118 IPF
prognostic predictor genes (66 %) was functionally
connected in these five gene networks, supporting a
concordance between expression correlations and func-
tional connections of individual genes. The first of the
five gene interaction networks is displayed in Additional
file 3: Figure S2 showing that five hub genes have signifi-
cantly higher degree of linkage to other nodes in the net-
work including ras homolog gene family member H
(RHOH), G protein-coupled receptor 18 (GPR18), G
protein-coupled receptor 171 (GPR171), and G protein-
coupled receptor 174 (GPR174), and lymphocyte-specific
protein tyrosine kinase (LCK).
Construction and cross-validation of a functional genomic
model for prognosis prediction
To determine prognosis prediction power of the gene set,
we constructed a novel functional genomic model using
“Survival risk group prediction” implemented in BRB-
Fig. 1 Correlation of gene co-expression modules with clinical traits in training cohort (n = 45). Gene co-expression modules were constructed
using R package WGCNA (see Methods and Additional file 1 for detail), and denoted by different colors. The parameters for topological overlap
matrix generation and unsupervised gene clustering are displayed in Additional file 3: Figure S2A & S2B. The number of genes in each gene
module is labeled on left. The module eigengene is the principal component of each gene module computed across all samples. Correlation of
module eigengene with each clinical trait was determined by Pearson’s correlation algorithm and displayed in the corresponding box (coefficient
on top and p-value in parenthesis on bottom). The color of each box represents the direction of correlation (red) or anti-correlation (green) and
the degree of correlations are scaled by the bar on the right. Traits significantly associated with specific modules are highlighted with a purple
frame. FVC % predicted = forced vital capacity percent predicted; DLCO % predicted = diffusion capacity of carbon monoxide percent predicted;
CPI = composite physiologic index
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Fig. 2 Compilation and functional characterization of IPF prognostic predictor gene set. a A flowchart illustrates the procedures and approaches
used for IPF prognostic predictor gene set compilation. Left panel: Arrary data processing. Affymetrix Exon 1.0 ST Array data was normalized, probe sets
mapped to U133 plus 2 Array, and filtered based on redundancy, intensity, and coefficient of variation across all samples. Middle panel: IPF prognostic
predictor gene set compilation. Three approaches used to compile IPF prognostic predictor gene set: Co-expressed gene modules correlated with
pulmonary function identified by WGCNA; Differentially expressed genes between “good” and “poor” prognosis patients identified by SAM (fold
change > 1.5 & FDR < 2.5 %); Survival-correlated genes identified by Cox regression (p < 0.005). Right panel: Genomic model IPF prognosis prediction. IPF
prognostic predictor gene set was used to construct a genomic model; Prognostic Index (PI) score was calculated from each patient in training
cohort; Prediction specificity was assessed by 10-fold cross validation; Genomic model was validated in two independent cohorts using weights of PI
calculated from training cohort. b Venn diagram illustrates the selection criteria for IPF prognostic predictor genes. A total of 118 genes were compiled
for downstream data analyses. c Canonical pathways enriched from IPF prognostic predictor genes by Ingenuity Pathway Analysis software. Significant
pathways were set with criterion of q-value < 0.05 (i.e. -log (q-value) > 1.3) using one-tailed Fisher’s exact test. X-axis represents -log (q-value)
Table 2 List of 118 IPF prognostic predictor genes within the red, black and turquoise gene modules
Gene FC Gene FC Gene FC Gene FC
IL1R2¥ 2.0 PPWD1 −1.7 ASF1A −1.6 ABCD2 −1.5
ERAF§ 2.0 CETN3 −1.6 LMO7 −1.6 GZMK −1.5
CEACAM8¥ 1.8 SH2D1A −1.6 GCET2 −1.6 TRIM52 −1.5
ARG1¥ 1.6 SLC39A10 −1.6 PAQR8 −1.6 C8orf15 −1.5
FOXO3§ 1.5 SHPRH −1.6 BIRC3 −1.6 ITK −1.5
TNS1§ 1.5 WDR75 −1.6 CAMK4 −1.6 ICOS −1.5
CYP4F2¥ 1.5 C14orf64 −1.6 ZC3H6 −1.6 FHIT −1.5
CYP4F3¥ 1.5 KPNA5 −1.6 CD28 −1.6 TSEPA −1.5
ARHGAP5 −1.8 NOP58 −1.6 GTPBp0 −1.6 NPCDR1 −1.5
ORC3L −1.8 PARp5 −1.6 C5orf51 −1.6 OXNAD1 −1.5
ZNF100 −1.8 PRO0471 −1.6 TRBC1 −1.6 IL7R −1.5
UTp5 −1.8 RCAN3 −1.6 CAMK2D −1.5 HLA-DQA1 −1.5
ANKRD36B −1.8 C7orf64 −1.6 PPM1K −1.5 TMEM156 −1.5
LOC399753 −1.8 ANKRD36 −1.6 CCDC76 −1.5 HLA-DQA1 −1.5
KCNA3 −1.8 GPR174 −1.6 CASD1 −1.5 LOC401397 −1.5
RHOH −1.8 NDUFAF4 −1.6 pRY10 −1.5 CDK6 −1.5
LCK −1.8 CCDC141 −1.6 DPP4 −1.5 GCNT4 −1.5
C16orf52 −1.7 GPR18 −1.6 S1PR1 −1.5 NELL2 −1.5
TC2N −1.7 DDX60 −1.6 ITGA6 −1.5 FLJ33630 −1.5
HIVEp −1.7 TMEM209 −1.6 GBP4 −1.5 TRAT1 −1.5
KIF3A −1.7 GVIN1 −1.6 ABCE1 −1.5 LEF1 −1.5
IFT80 −1.7 TMEM161B −1.6 TXK −1.5 FCRL3 −1.5
TIA1 −1.7 USP53 −1.6 TRAF5 −1.5 GUSBL2 −1.5
ZNF83 −1.7 TRAJ17 −1.6 SLAMF6 −1.5 SEPSECS −1.5
SETDB2 −1.7 MRPL1 −1.6 CD96 −1.5 BTLA −1.5
WDR36 −1.7 SNORD116 −1.6 PRKACB −1.5
ZNF141 −1.7 GPR171 −1.6 ALG10B −1.5
TRBC1 −1.7 MGC40069 −1.6 NBPF10 −1.5
FAM69A −1.7 LOC439949 −1.6 MGAT4A −1.5
C1GALT1 −1.7 CCR7 −1.6 INPP4B −1.5
GIMAP5 −1.7 NUP43 −1.6 STAT4 −1.5
FC = Fold change; ¥denotes genes in red module; §denotes genes in black module; the rest of genes are in turquoise module
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ArrayTools. The output of the genomic model is a patient-
specific prognostic index (PI). The genomic model was
displayed in Fig. 3a, where Wi and Xi represented the
weight and log-intensity of the i-th gene in the gene set
identified from training cohort. Based on previous clinical
observation, we empirically set the percentile population of
low vs. high risk to the lower tertiles vs. upper tertile, re-
spectively. Patients in the training cohort were categorized
as low or high risk based on whether the patient-specific PI
fell in the lower tertiles vs. upper tertile, respectively. We
obtained PI values ranging from −2.14 to 3.45, which were
continuously associated with risk of death.
Of the 45 individuals in the training cohort, 30
(66.7 %) and 15 (33.3 %) were assigned to the low risk or
high risk groups, respectively based on PI. Misclassifica-
tion rate was determined by comparison of the predicted
class to clinically observed outcomes in the training co-
hort, in which 28 patients were with “good” and 17 with
“poor” prognosis (Fig. 3a). Ten-fold cross-validation
(CV) demonstrated a low misclassification rate of 20 %.
In order to estimate the variance, we repeated the 10
fold CV 10 times with random partitions of the training
cohort. The range of misclassification was 17 % ~ 23 %.
Survival was significantly better among those classified
as low risk (p < 0.001 compared to high risk) based on PI
score (Fig. 3b). PI independently predicted survival in
univariate competing-risk Cox regression (Sub-hazard
ratio (SHR) 2.7; 95 % CI 1.9-3.9; p < 0.001) and in
multivariate competing-risk Cox regression after adjust-
ment for baseline CPI (SHR 2.3; 95 % CI 1.5-3.4;
p < 0.001).
IPF genomic model predicts prognosis in two
independent validation cohorts
The IPF genomic model shown in Fig. 3a was applied to
two independent validation cohorts, UCV and UPV,
where two microarray platforms (Affymetrix and Agilent,
respectively) were used. The weight of each gene and the
constant (13.5) derived from training cohort were carried
over for independent validation of the genomic model.
After annotating the gene expression data from each co-
hort with UniGene annotations, 10 of the IPF prognostic
predictor genes did not map to Agilent Human 4x44k
Whole Genome Expression array in UPV. Therefore, we
computed the PI using 108 classifiers for UPV and 118
classifiers for UCV, respectively. Individuals in the UCV
and UPV cohorts were classified as low vs. high risk based
on whether the patient-specific PI fell in the lower tertiles
vs. upper tertile, respectively, as was done for the training
cohort. In both validation cohorts, patients classified as
low risk demonstrated significantly improved survival
over those classified as high risk (p < 0.001 for UCV
and p = 0.002 for UPV) (Fig. 4a&b). PI remained a signifi-
cant predictor of survival in univariate competing-event
Cox regression in the UCV (SHR 2.0; 95 % CI 1.2-3.4;
p = 0.005) and UPV (SHR 1.8; 95 % CI 1.1-2.7; p = 0.01)
A B
Fig. 3 Genomic model and 10-fold cross validation results. a A genomic model was constructed from the 118 IPF prognostic predictor genes
using “Survival risk group prediction” algorithm implemented in BRB-ArrayTools (see Additional file 1) followed by 10-fold cross validation (CV)
algorithm to calculate the misclassification rate. Formula of genomic model: Prognostic index (PI) = ∑Wi * Xi +13.5, where Wi and Xi represent the
weight and log-intensity of the i-th gene in IPF prognostic predictor gene set compiled from training cohort, respectively. Misclassification rate
(20 %) was determined by 10-fold CV and computed as (k + n)/total cases, where k represents the predicted high risk that are observed as good
prognosis, and n represents the predicted low risk that are observed as poor prognosis. b IPF patients with predicted low (dotted line) and high
risk (dashed line) stratified by prognostic index (PI) derived from each patient in training cohort based on the genomic model. The red line
denotes 50 % probability of survival. PI independently predicted survival in univariate competing-risk Cox regression (Sub-hazard ratio (SHR) 2.7;
95 % CI 1.9-3.9; p < 0.001) and in multivariate competing-risk Cox regression after adjustment for baseline CPI (SHR 2.3; 95 % CI 1.5-3.4; p < 0.001)
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cohorts. This association remained in the UCV (SHR 1.7;
95 % CI 1.04-2.93; p = 0.035) and UPV (SHR 1.9; 95 % CI
1.2-3.0; p = 0.005) cohorts after adjusting for baseline CPI
in multivariate Cox regression.
To evaluate the biological reproducibility of IPF prog-
nostic predictor genes within the set, fold change of each
gene was calculated between predicted low-risk and
high-risk prognosis patients in each cohort, and then
regressed between training versus each validation cohort.
The regression plot revealed a strong concordance of
fold changes between training and each validation cohort
(Additional file 4: Figure S3). Pearson’s correlation analysis
showed significant correlation of the classifier fold
changes between training and UCV (p = 2.2 × 10−16) as
well as between training and UPV cohort (p = 1.4 × 10−8).
Multivariate correlation of Prognostic Index with clinical
parameters
We investigated the impact of clinical parameters on the
genomic model (Additional file 1: Table S2). Pearson’s cor-
relation analysis showed that PI was significantly corre-
lated with CPI in the training (coefficient = 0.36, p = 0.016)
and UCV (coefficient = 0.53, p = 0.01) cohorts, but not in
UPV cohort (coefficient = −0.05, p = 0.69). While the PI of
an individual sample was not associated with age, it was
significantly higher in males compared to females in the
training and UPV cohorts (p = 0.02 and 0.04, respectively).
The impact of ethnic diversity on PI was evaluated
and no difference was found between Caucasian and
non-Caucasian in the training (p = 0.92) and UCV co-
hort (p = 0.79) despite each cohort containing 18 %
non-Caucasians (Additional file 1: Table S2). This re-
sult was consistent with the data obtained from
WGCNA analysis showing the turquoise gene module
was significantly correlated with female gender (Fig. 1,
coefficient = −0.39, p = 0.009).
Application of genomic model in IPF diagnosis
To evaluate whether our genomic model is able to dis-
criminate IPF patients from healthy individuals, we con-
ducted the ROC analysis of the PI by plotting the true
positive (sensitivity) versus false alarm (1-specificity). PI
accurately distinguished IPF subjects from healthy individ-
uals in the UCV cohort with an AUC 0.96. The sensitivity
of IPF diagnosis by PI at 10 % false alarm was 80 % (red
line in Additional file 5: Figure S4).
Discussions
In this study, we constructed a functional genomic model
that predicted survival in three independent cohorts of
IPF patients. In the training cohort, we analyzed genomic
data using both unsupervised WGCNA and supervised
SAM approaches. By applying WGCNA algorithm, we
first associated the pathophysiological alterations in the
transcriptome level to the clinic traits of IPF and found
55 % of the genes clustered into the turquoise, black and
red modules which were significantly correlated with pul-
monary function. In a parallel analysis, 95 % of the differ-
entially expressed genes between IPF patients with good
and poor prognosis identified by SAM were attributed to
these three pulmonary function associated gene modules.
A B
Fig. 4 IPF genomic model predicts prognosis in two independent validation cohorts. The prognosis prediction specificity was assessed in
University of Chicago validation cohort (UCV, panel a) and University of Pittsburgh validation cohort (UPV, panel b). IPF patients with predicted
low (dotted line) and high risk (dashed line) stratified by prognostic index (PI) derived from each patient in UCV and UPV cohorts based on the
genomic model. The red line denotes 50 % probability of survival. PI significantly predicted survival in univariate competing-event Cox regression
in the UCV (SHR 2.0; 95 % CI 1.2-3.4; p = 0.005) and UPV (SHR 1.8; 95 % CI 1.1-2.7; p = 0.01) cohorts. This association remained in the UCV (SHR 1.7;
95 % CI 1.04-2.93; p = 0.035) and UPV (SHR 1.9; 95 % CI 1.2-3.0; p = 0.005) cohorts after adjusting for baseline CPI in multivariate Cox regression
Huang et al. BMC Pulmonary Medicine  (2015) 15:147 Page 9 of 12
This analytical pipeline highlights the potential applicabil-
ity of an unsupervised correlation network approach,
whereby functional characterization of correlated gene
modules provides insight into the molecular mechanisms
underlying a clinical trait of a complex pulmonary disease.
Lastly, we correlated gene expression levels with survival,
which contributed another important feature of IPF. We
defined genes met all three selection criteria as “IPF prog-
nostic predictor genes”.
Pathway analysis of the IPF prognostic predictor genes
revealed several canonical pathways including T-cell recep-
tor signaling pathway in turquoise module (q = 0.0087);
hemoglobin metabolic process and oxygen transport in
black module (q = 0.0031 and 0.0032, respectively); and
defense response to bacterium and neutrophil degranula-
tion in red module (q = 0.000 and 0.0041, respectively)
(Additional file 1: Table S3). The enriched T-cell biology,
including iCOS signaling in T-helper cells, CD28 signaling,
and T-helper cell differentiation is supported by our prior
work, with similar analyses of a smaller gene set demon-
strating that decreased expression of CD28, ICOS, LCK,
and ITK predicted mortality in patients with IPF [16]. Im-
paired regulatory T-cells from bronchoalveolar lavage fluid
have been strongly correlated with pulmonary dysfunction
of IPF patients [28]. Down-regulation of CD28 on circulat-
ing CD4 T-cells has been associated with poor outcomes
in IPF patients [29]. IL-17A, a cytokine produced by CD4+
and gamma-delta+ T cells, has been shown to play a critical
role in inducing fibrosis in a mouse model [30]. Although
the role of the immune system in IPF remains unclear, a
large multicenter study has shown that IPF patients treated
with prednisone and azathioprine had an increased risk of
death and hospitalization compared to those receiving pla-
cebo [31]. It remains unknown whether a down-regulated
immune system is causally involved in IPF pathogenesis, or
is the result of primary lung injury. In addition, a down-
regulated immune system could result in a reduced T-cell
population [32, 33]. Nevertheless, the down-regulated T-
cell pathways or reduced T-cell population can both lead
to impaired immune function. These studies are congruent
with the functional profile of our IPF genomic model sug-
gesting that suppression of the immune system with medi-
cations such as prednisone and azathioprine may worsen
the clinical course for IPF patients whose immune systems
are already down-regulated.
By evaluating the performance of the genomic model in
two independent validation cohorts with different micro-
array platforms performed at different medical centers, we
demonstrate the potential applicability of our findings for
real-world use. Notably, the prognostic index (PI) derived
from the genomic model showed consistent prognostic pre-
diction specificity in each validation cohort and produced
similar mortality hazard estimation across all three cohorts.
Genomic model constructed using IPF prognostic predictor
genes also displayed concordant fold changes between pa-
tients with predicted low- and high-risk prognosis in train-
ing and validation cohorts. Furthermore, the PI was able to
discriminate between IPF and healthy controls with great
accuracy, suggesting a future potential screening tool. How-
ever, it is unclear whether the PI can distinguish IPF pa-
tients from patients with other pulmonary fibrotic diseases
such as nonspecific interstitial pneumonia (NSIP), hyper-
sensitivity pneumonitis (HP), and respiratory bronchiolitis-
associated interstitial lung disease (RB-ILD) etc. This ques-
tion can be addressed in future studies.
While the genomic model developed in this study has
been successfully validated in two independent (UCV and
UPV) cohorts, certain technical issues and potential clin-
ical confounders require further study. First, there were
demographic differences in gender and race between the
training and UPV cohorts. The training population was
strongly biased towards male patients, while the UPV
population was more balanced with respect to gender.
There was a greater prevalence of Caucasians in the UPV
cohort. Interestingly, the PI scores were higher and indica-
tive of poorer outcome in women overall, while being pri-
marily derived from a male cohort. While IPF is more
common in men than women [31], women appear to have
improved survival [34, 35]. Although the reasons for this
clinical observation are unclear, our results indicate that
there may be differential gene expressions between male
and female patients with IPF that underlie this observation.
In addition, the different microarray platforms used in
different cohort studies might affect the prediction spe-
cificity of the model. Notably, the correlation of the PI
with pulmonary function in UPV cohort is less strong
compared to that in training and in UCV cohorts. We
speculated that this observation may be partially attrib-
uted to the loss of the 10 classifiers when mapped from
Affymetrix to Agilent microarray platform. Another po-
tential confounding factor is the higher rate of lung trans-
plant in the UPV cohort (20 %) compared to the UCV
cohorts (7 %). We attempted to adjust for this in our sur-
vival analysis by treating transplant as a competing event.
Validation with a larger prospective cohort would be
beneficial. Finally, the PI cannot be standardized across
different microarray platforms, because the gene expres-
sion levels in microarray assay were measured by arbitrary
fluorescent intensities rather than transcript copy num-
bers. Therefore, an absolute cut-off or carry-over of PI
across individual studies is not feasible, and clinical elab-
oration of the hazard ratio of PI is impractical at this stage.
Future approaches with direct assessment of these IPF
prognostic predictor genes could overcome this issue.
Conclusions
We identified an IPF genomic model with both diagnos-
tic and prognostic prediction ability. The unsupervised
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WGCNA analysis appears to be a promising approach to
elucidate the molecular mechanism underlying IPF pro-
gression as an extension of its previous use in oncologic
studies [36–38]. The genomic model constructed from the
IPF prognostic predictor genes demonstrated robust clin-
ical applications. Functional analysis of the IPF prognostic
predictor genes strongly supported the involvement of
T-cell immune response in IPF progression [29, 39]. These
data continue to support and highlight the use of genomic
profiles from the peripheral blood for pulmonary disease.
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Additional file 1: Additional Methods and Tables. (DOCX 103 kb)
Additional file 2: Figure S1. Detection of gene co-expression modules
in training cohort. Gene expression intensities obtained from Exon 1.0 ST
Array were normalized. Probe sets were mapped to U133 plus 2.0 Array
and filtered as described in Additional file 1. A total of 2,718 unique
genes were retained and subjected to R package “Weighted Gene
Co-expression Network Analysis (WGCNA)” to identify co-expressed gene
modules. A). Optimization and selection of power for adjacency transition
of gene-gene correlation matrix (power =7). B). Cluster dendrogram of
the gene co-expression modules represented by different colors. Seven
gene co-expression modules were detected by hierarchical clustering
using dynamic tree cut algorithm integrated in WGCNA with the following
parameters: power=7, minModuleSize=120, mergeCutHeight= 0.3. Unclustered
genes (genes not correlated with other genes) were collected in Grey module.
(PPTX 187 kb)
Additional file 3: Figure S2. Gene interaction network of IPF prognostic
predictor genes. Significant gene interaction networks were determined
using Ingenuity Pathway Analysis (IPA) software. Node shapes denoting
different functions were depicted in right panel box. Green and red denote
down and up-regulated genes, respectively. (PPTX 544 kb)
Additional file 4: Figure S3. Concordance of IPF prognostic predictor
genes between training and each validation cohort. The fold change of
each gene between predicted low-risk and high-risk prognosis patients
was plotted between training (X-axis) and validation cohort (Y-axis).
(PPTX 51 kb)
Additional file 5: Figure S4. Receiver-Operating-Characteristic (ROC)
analysis of genomic model for diagnosis prediction. ROC curves of UCV
cohort consisting of IPF patients and healthy individuals were plotted
based on the Prognostic Index (PI) derived from IPF genomic model.
AUC (Area-Under-Curve) is displayed in the graph. The red line denotes
10 % false alarm (1-Specificity). (PPTX 79 kb)
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